Pharmaceutical

China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG

China’s NMPA has granted approval for Zai Lab and argenx's efgartigimod SC for the treatment of generalised myasthenia gravis (gMG).

Jul 18, 2024 - 04:00
China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG
China’s NMPA has granted approval for Zai Lab and argenx's efgartigimod SC for the treatment of generalised myasthenia gravis (gMG).
Read the original article

Tags:

Previous Article

Scorpion Therapeutics secures $150m for oncology pipeline

Next Article

FDA issues CRL to Orexo’s NDA for opioid overdose medication

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Alvotech and Bioventure gain approval for Humira biosimilar in Egypt

Alvotech and Bioventure gain approval for Humira biosim...

Aug 30, 2023

Amid a dire nationwide therapist shortage, could lay counselors help close the gap?

Amid a dire nationwide therapist shortage, could lay co...

Jan 18, 2024

STAT+: Could sickle cell someday be treated not with CRISPR, but with a pill?

STAT+: Could sickle cell someday be treated not with CR...

Dec 13, 2023